Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Average (2022 - 2025)

Historic Equity Average for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $3.4 million.

  • bioAffinity Technologies' Equity Average rose 323.38% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 323.38%. This contributed to the annual value of $3.7 million for FY2024, which is 5309.5% down from last year.
  • bioAffinity Technologies' Equity Average amounted to $3.4 million in Q3 2025, which was up 323.38% from -$348352.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Equity Average registered a high of $11.8 million during Q4 2022, and its lowest value of -$348352.0 during Q2 2025.
  • Its 4-year average for Equity Average is $5.4 million, with a median of $4.7 million in 2024.
  • Within the past 5 years, the most significant YoY rise in bioAffinity Technologies' Equity Average was 323.38% (2025), while the steepest drop was 10801.72% (2025).
  • Quarter analysis of 4 years shows bioAffinity Technologies' Equity Average stood at $11.8 million in 2022, then plummeted by 49.88% to $5.9 million in 2023, then tumbled by 51.7% to $2.9 million in 2024, then increased by 18.23% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, -$348352.0 for Q2 2025, and $2.0 million during Q1 2025.